Blueprint Medicines Co. (NASDAQ:BPMC) COO Sells $250,458.36 in Stock

Blueprint Medicines Co. (NASDAQ:BPMC) COO Christina Rossi sold 2,274 shares of the stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $110.14, for a total value of $250,458.36. Following the sale, the chief operating officer now directly owns 67,109 shares in the company, valued at approximately $7,391,385.26. This trade represents a 3.28 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Christina Rossi also recently made the following trade(s):

• On Wednesday, December 18th, Christina Rossi sold 2,274 shares of Blueprint Medicines stock. The stock was sold at an average price of $95.91, for a total transaction of $218,099.34.
• On Wednesday, November 27th, Christina Rossi sold 2,274 shares of Blueprint Medicines stock. The shares were sold at an average price of $95.10, for a total transaction of $216,257.40.

Blueprint Medicines Price Performance

Shares of NASDAQ:BPMC opened at $114.91 on Friday. The company has a debt-to-equity ratio of 1.09, a quick ratio of 3.27 and a current ratio of 3.32. Blueprint Medicines Co. has a 52 week low of $72.24 and a 52 week high of $121.90. The firm has a market cap of $7.30 billion, a PE ratio of -54.46 and a beta of 0.61. The firm’s fifty day moving average is $95.80 and its 200-day moving average is $95.47.

Blueprint Medicines (NASDAQ:BPMC) last announced its earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) EPS for the quarter, topping the consensus estimate of ($0.97) by $0.08. The firm had revenue of $128.20 million for the quarter, compared to the consensus estimate of $127.56 million. Blueprint Medicines had a negative return on equity of 112.30% and a negative net margin of 29.48%. The business’s quarterly revenue was up 126.5% compared to the same quarter last year. During the same period in the previous year, the business earned ($2.20) EPS. Sell-side analysts predict that Blueprint Medicines Co. will post -3.67 earnings per share for the current year.

Institutional Trading of Blueprint Medicines

Several institutional investors have recently added to or reduced their stakes in the stock. Quarry LP bought a new position in Blueprint Medicines during the 3rd quarter worth approximately $32,000. R Squared Ltd acquired a new stake in shares of Blueprint Medicines during the fourth quarter worth $51,000. Covestor Ltd raised its stake in Blueprint Medicines by 206.7% during the third quarter. Covestor Ltd now owns 598 shares of the biotechnology company’s stock worth $55,000 after buying an additional 403 shares during the last quarter. Quantbot Technologies LP acquired a new position in Blueprint Medicines in the third quarter valued at $108,000. Finally, Values First Advisors Inc. bought a new stake in Blueprint Medicines during the third quarter valued at $122,000.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Wedbush reiterated an “outperform” rating and set a $124.00 price target (down previously from $135.00) on shares of Blueprint Medicines in a research report on Monday, January 13th. Guggenheim reaffirmed a “buy” rating on shares of Blueprint Medicines in a report on Wednesday, December 11th. Needham & Company LLC reissued a “buy” rating and set a $135.00 price target on shares of Blueprint Medicines in a report on Monday, January 13th. JMP Securities reaffirmed a “market outperform” rating and issued a $125.00 price objective on shares of Blueprint Medicines in a research note on Wednesday, January 15th. Finally, HC Wainwright reissued a “buy” rating and set a $135.00 target price on shares of Blueprint Medicines in a research note on Friday, November 15th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $122.72.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.